Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
Sponsor: University Hospital, Alexandroupolis
Summary
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration. It is known that previous anti-VEGF agents has systematic absorption and may cause deterioration in renal function of the patients. However, the effect of Faricimab on kidney function has not been investigated yet. Taking into account that Ang-2 has destructive effect on kidneys, the investigation of the effect of its inhibition in diabetic patients who have already renal function deterioration may provide a valuable information in scientific community.
Official title: The Impact of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Faricimab on Renal Function in Patients With Diabetes Mellitus
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-03-10
Completion Date
2027-03-10
Last Updated
2025-04-24
Healthy Volunteers
No
Conditions
Interventions
Intravitreal injection of Faricimab or Aflibercept 2 mg
Anti-VEGF agents Faricimab (Vabysmo) or Aflibercept 2 mg (Eylea) will be delivered intravitreally
Locations (2)
University Hospital of Alexandroupolis
Alexandroupoli, Evros, Greece
University Hospital of Alexandroupolis
Alexandroupoli, Greece